DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Herbst RS, Baas P, Kim D-W. et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet 2016;
387 (10027): 1540-1550
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.